Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Vasculitis: A CLEAR argument for targeting complement in ANCA vasculitis. Nat Rev Nephrol (2017) 0.75

Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int (2017) 0.75

Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss. Mol Neurodegener (2017) 0.75

The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol (2017) 0.75

Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics (1975) 18.25

Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med (2010) 8.64

MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol (2008) 2.00

C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93

C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol (2008) 1.92

Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med (1979) 1.87

Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis (2009) 1.86

Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2003) 1.46

Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol (2008) 1.44

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis (2016) 1.44

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM (2000) 1.44

C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol (2013) 1.38

Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood (2010) 1.31

Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol (2011) 1.20

Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol (2002) 1.15

Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis (2008) 1.08

Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant (2004) 1.07

Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. Rheumatology (Oxford) (2011) 1.05

Endothelium-neutrophil interactions in ANCA-associated diseases. J Am Soc Nephrol (2012) 1.02

Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int (2013) 1.00

Complement-induced granulocyte aggregation in vivo. Am J Pathol (1981) 1.00

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2013) 0.98

Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) (2002) 0.97

Mortality in Wegener's granulomatosis: a bimodal pattern. Rheumatology (Oxford) (2010) 0.96

Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol (2012) 0.94

Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant (2003) 0.94

Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford) (2000) 0.90

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis (2008) 0.90

ANCA-induced neutrophil F-actin polymerization: implications for microvascular inflammation. Kidney Int (2005) 0.87

Effects of single dose compared with three days' prednisolone treatment of healthy volunteers: contrasting effects on circulating lymphocyte subsets. J Clin Pathol (1993) 0.83

With complements from ANCA mice. J Am Soc Nephrol (2013) 0.83

Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial. Clin J Am Soc Nephrol (2016) 0.80

A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol (2014) 0.76

Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA (+) vasculitis: a single-center experience. J Nephrol (2005) 0.75

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One (2016) 0.75

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) (2014) 0.75

Wegener's granulomatosis in Finland in 1981-2000: risk of dialysis-dependent renal disease. Scand J Rheumatol (2011) 0.75